Christel Hero1, Araz Rawshani2, Ann-Marie Svensson3, Stefan Franzén3, Björn Eliasson2, Katarina Eeg-Olofsson2, Soffia Gudbjörnsdottir4. 1. Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden christel.hero@vgregion.se. 2. Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden. 3. Swedish National Diabetes Register, Gothenburg, Sweden. 4. Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden Swedish National Diabetes Register, Gothenburg, Sweden.
Abstract
OBJECTIVE: To evaluate the effect of lipid-lowering therapy (LLT) in primary prevention on cardiovascular disease (CVD) and death in type 1 diabetes. RESEARCH DESIGN AND METHODS: We used the Swedish National Diabetes Register (NDR) to perform a propensity score-based study. Propensity scores for treatment with LLT were calculated from 32 baseline clinical and socioeconomic variables. The propensity score was used to estimate the effect of LLT in the overall cohort (by stratification). We estimated risk of acute myocardial infarction, stroke, coronary heart disease, and cardiovascular and all-cause mortality in individuals with and without LLT using Cox regression. A total of 24,230 individuals included in 2006-2008 NDR with type 1 diabetes without a history of CVD were followed until 31 December 2012; 18,843 were untreated and 5,387 treated with LLT (97% statins). The mean follow-up was 6.0 years. RESULTS: The propensity score allowed balancing of all 32 covariates, with no differences between treated and untreated after accounting for propensity score. Hazard ratios (HRs) for treated versus untreated were as follows: cardiovascular death 0.60 (95% CI 0.50-0.72), all-cause death 0.56 (0.48-0.64), fatal/nonfatal stroke 0.56 (0.46-0.70), fatal/nonfatal acute myocardial infarction 0.78 (0.66-0.92), fatal/nonfatal coronary heart disease 0.85 (0.74-0.97), and fatal/nonfatal CVD 0.77 (0.69-0.87). CONCLUSIONS: This observational study shows that LLT is associated with 22-44% reduction in the risk of CVD and cardiovascular death among individuals with type 1 diabetes without history of CVD and underlines the importance of primary prevention with LLT to reduce cardiovascular risk in type 1 diabetes.
OBJECTIVE: To evaluate the effect of lipid-lowering therapy (LLT) in primary prevention on cardiovascular disease (CVD) and death in type 1 diabetes. RESEARCH DESIGN AND METHODS: We used the Swedish National Diabetes Register (NDR) to perform a propensity score-based study. Propensity scores for treatment with LLT were calculated from 32 baseline clinical and socioeconomic variables. The propensity score was used to estimate the effect of LLT in the overall cohort (by stratification). We estimated risk of acute myocardial infarction, stroke, coronary heart disease, and cardiovascular and all-cause mortality in individuals with and without LLT using Cox regression. A total of 24,230 individuals included in 2006-2008 NDR with type 1 diabetes without a history of CVD were followed until 31 December 2012; 18,843 were untreated and 5,387 treated with LLT (97% statins). The mean follow-up was 6.0 years. RESULTS: The propensity score allowed balancing of all 32 covariates, with no differences between treated and untreated after accounting for propensity score. Hazard ratios (HRs) for treated versus untreated were as follows: cardiovascular death 0.60 (95% CI 0.50-0.72), all-cause death 0.56 (0.48-0.64), fatal/nonfatal stroke 0.56 (0.46-0.70), fatal/nonfatal acute myocardial infarction 0.78 (0.66-0.92), fatal/nonfatal coronary heart disease 0.85 (0.74-0.97), and fatal/nonfatal CVD 0.77 (0.69-0.87). CONCLUSIONS: This observational study shows that LLT is associated with 22-44% reduction in the risk of CVD and cardiovascular death among individuals with type 1 diabetes without history of CVD and underlines the importance of primary prevention with LLT to reduce cardiovascular risk in type 1 diabetes.
Authors: Araz Rawshani; Naveed Sattar; Stefan Franzén; Aidin Rawshani; Andrew T Hattersley; Ann-Marie Svensson; Björn Eliasson; Soffia Gudbjörnsdottir Journal: Lancet Date: 2018-08-09 Impact factor: 79.321
Authors: Richard I G Holt; J Hans DeVries; Amy Hess-Fischl; Irl B Hirsch; M Sue Kirkman; Tomasz Klupa; Barbara Ludwig; Kirsten Nørgaard; Jeremy Pettus; Eric Renard; Jay S Skyler; Frank J Snoek; Ruth S Weinstock; Anne L Peters Journal: Diabetologia Date: 2021-12 Impact factor: 10.122
Authors: Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Mary E Gearing; Alisha V Ling; Kathryn A Williams; Ji Miao; Stuart S Adamson; Dong-Ju Shin; Satyapal Chahar; Mark J Graham; Rosanne M Crooke; Lee R Hagey; David Vicent; Sarah D de Ferranti; Srividya Kidambi; Clary B Clish; Sudha B Biddinger Journal: Circulation Date: 2022-02-23 Impact factor: 39.918
Authors: Martin Heier; Mark S Borja; Cathrine Brunborg; Ingebjørg Seljeflot; Hanna Dis Margeirsdottir; Kristian F Hanssen; Knut Dahl-Jørgensen; Michael N Oda Journal: Cardiovasc Diabetol Date: 2017-07-06 Impact factor: 9.951
Authors: Viral N Shah; Ryan Bailey; Mengdi Wu; Nicole C Foster; Rodica Pop-Busui; Michelle Katz; Jill Crandall; Fida Bacha; Kristen Nadeau; Ingrid Libman; Paul Hiers; Kara Mizokami-Stout; Linda A DiMeglio; Jennifer Sherr; Richard Pratley; Shivani Agarwal; Janet Snell-Bergeon; Eda Cengiz; Sarit Polsky; Sanjeev N Mehta Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958